Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) EBITDA Margin (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of EBITDA Margin data on record, last reported at 141.24% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 49581.0% year-over-year to 141.24%; the TTM value through Dec 2025 reached 34.25%, up 83700.0%, while the annual FY2025 figure was 34.25%, 83700.0% up from the prior year.
  • EBITDA Margin reached 141.24% in Q4 2025 per VRCA's latest filing, down from 11.34% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 354.57% in Q4 2024 and bottomed at 17808.11% in Q1 2023.
  • Average EBITDA Margin over 5 years is 2546.45%, with a median of 486.12% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: crashed -1583525bps in 2023, then surged 1732199bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 7.78% in 2021, then plummeted by -111432bps to 8680.88% in 2022, then skyrocketed by 86bps to 1238.13% in 2023, then surged by 129bps to 354.57% in 2024, then plummeted by -140bps to 141.24% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 141.24% in Q4 2025, 11.34% in Q3 2025, and 11.89% in Q2 2025.